文献速递乳腺癌支持与姑息治疗

中国早期乳腺癌化疗中PEG-rhG-CSF初级预防的成本-效果分析

[Cost-effectiveness of primary prophylaxis with PEG-rhG-CSF in early-stage breast cancer patients receiving chemotherapy in China].
PubMed 文献 · Zhonghua Zhong Liu Za Zhi · 2020-01-01

该研究构建两阶段Markov模型,模拟45岁Ⅱ期乳腺癌患者接受TC×4化疗(FN风险>20%)时,PEG-rhG-CSF初级预防对比rhG-CSF初级预防或无预防的成本-效果。结果显示PEG-rhG-CSF的增量成本-效果比分别为79 146.3元/QALY和17 558.77元/QALY,均低于WHO建议的3倍人均GDP意愿支付阈值。

要点

  • PEG-rhG-CSF初级预防较rhG-CSF和无预防的ICER分别为79 146.3元/QALY和17 558.77元/QALY。
  • 两项ICER均低于WHO建议的3倍人均GDP意愿支付阈值18 000元。
  • FN风险>20%的中国早期乳腺癌患者中PEG-rhG-CSF初级预防具成本-效果优势。

核心结论

  • 尽管PEG-rhG-CSF初级预防成本较高,但考虑额外收益,对中国FN风险>20%的早期乳腺癌患者是具成本-效果的替代方案。

研究设计与样本

  • 构建两阶段Markov模型,假定队列为45岁Ⅱ期乳腺癌患者。
  • 第一阶段模拟4周期多西他赛联合环磷酰胺(TC×4,FN风险>20%)化疗的成本与结果。
  • 第二阶段模拟长期生存,并与相对剂量强度(RDI)关联。

主要发现

  • 与rhG-CSF初级预防相比,PEG-rhG-CSF成本增加5 208.19元,QALYs提高0.066年。
  • 与无预防相比,PEG-rhG-CSF成本增加5 222.73元,QALYs提高0.297年。
  • 敏感性分析显示PEG-rhG-CSF临床效果越好越具成本-效果优势。
  • RDI<85%对比≥85%的死亡风险比越低,PEG-rhG-CSF初级预防越具成本-效果优势。

关键数值与推荐

  • FN发生率基线0.29(确定性敏感性分析范围0.24~0.35)。
  • FN病死率3.4(2.7~4.1)。
  • RDI<85%对比≥85%的死亡风险比1.45(1.00~2.32)。
  • 增量成本-效果比分别为79 146.3元/QALY和17 558.77元/QALY。
  • 意愿支付阈值为WHO建议的3倍人均GDP,即18 000元。

临床怎么用

  • 对中国FN风险>20%的早期乳腺癌接受TC×4化疗患者,可考虑PEG-rhG-CSF初级预防作为具成本-效果的选择。

局限性

  • 模型假设基于文献综述和专家意见,部分参数缺乏已发表证据时采用专家意见估计。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To evaluate the cost effectiveness of primary prophylaxis (PP) with pegylated recombinant human granulocyte colony stimulating factor (PEG-rhG-CSF), PP with recombinant human granulocyte colony stimulating factor (rhG-CSF) and no prophylaxis in women with early-stage breast cancer in China. Methods: Two phase Markov models were constructed for a hypothetical cohort of patients aged 45 with stage Ⅱ breast cancer. The first phase modelled costs and outcomes of 4 cycles docetaxel combined with cyclophosphamide [TC×4, febrile neutropenia (FN) risk>20%] chemotherapy, which assumptions based on literature reviews, including FN rates [base-case (deterministic sensitivity analysis range), 0.29 (0.24-0.35)] and related events [FN case-fatality, 3.4 (2.7-4.1)]. Second phase modelled the long term survival which was link with the relative dose intensity (RDI) [mortality hazard ratio (HR) of RDI < 85% vs ≥85%, 1.45 (1.00-2.32)]. Clinical effectiveness, therapeutic costs, and economic utilities were estimated from peer-reviewed publications and expert opinions in case of unavailability of published evidences. Results: Compared to rhG-CSF PP and no prophylaxis, the cost of PEG-rhG-CSF PP increased to 5 208.19 RMB and 5 222.73 RMB, respectively. The quality-adjusted life-years (QALYs) enhanced to 0.066 and 0.297, respectively. Accordingly, the incremental cost effectiveness ratios (ICERs) are 79 146.3 RMB and 17 558.77 RMB per QALY, which were both below the willingness to pay (WTP) threshold of three times GDP per capita (18, 000 RMB) recommended by the WHO. Sensitivity analysis suggested that the more clinically effective the primary prophylaxis with PEG-rhG-CSF is, the more cost-effective primary prophylaxis with PEG-rhG-CSF will be. And the lower the mortality HR of RDI<85% vs ≥85% is, the more cost-effective primary prophylaxis with PEG-rhG-CSF will be. Conclusion: Although the cost of PP PEG-rhG-CSF is higher, considering the additional benefits, the administrating of PP PEG-rhG-CSF is likely to be a cost-effective alternative to PP rhG-CSF and no prophylaxis in patients with early stage breast cancer whose FN risks are more than 20% in China. 目的: 评估中国早期乳腺癌女性患者,接受聚乙二醇化重组人粒细胞刺激因子(PEG-rhG-CSF)初级预防与接受重组人粒细胞刺激因子(rhG-CSF)初级预防或无预防的成本-效果。 方法: 构建2种状态Markov模型,假定队列患者是年龄为45岁的Ⅱ期乳腺癌患者。第1种状态模拟4个周期多西他赛联合环磷酰胺[发热性中性粒细胞减少(FN)风险>20%]化疗的成本和结果,其假设基于文献综述,包括FN发生率[基线(确定敏感性分析范围),0.29(0.24~0.35)]和相关事件[FN病死率,3.4(2.7~4.1)]。第2种状态模拟长期生存,并与相对剂量强度(RDI)[RDI<85%和≥85%的死亡风险比为1.45(1.00~2.32)]进行关联。临床效果、治疗成本和经济学效用值是基于同行评审的出版物和专家意见。 结果: 与rhG-CSF初级预防和无预防治疗方案比较,PEG-rhG-CSF初级预防成本分别增加了5 208.19元和5 222.73元,质量调整生命年(QALYs)分别提高了0.066年和0.297年。因此,增量成本-效果比分别为79 146.3元/QALY和17 558.77元/QALY,均低于世界卫生组织建议的3倍人均国内生产总值(18 000元)的意愿支付阈值。敏感性分析显示,PEG-rhG-CSF初级预防的临床效果越好,越具有成本-效果优势。RDI<85%对比≥85%的死亡风险比越低,PEG-rhG-CSF初级预防越具有成本-效果优势。 结论: 尽管PEG-rhG-CSF初级预防的成本较高,但考虑到其额外的收益,中国FN风险>20%的早期乳腺癌患者采用PEG-rhG-CSF初级预防与rhG-CSF初级预防或无预防相比,PEG-rhG-CSF很可能是一种具有成本-效果的替代方法。.

来源:Zhonghua Zhong Liu Za Zhi,查看原文。版权归原作者所有。

引用

  1. Xia W, Wang SS, Hu H, et al. [Cost-effectiveness of primary prophylaxis with PEG-rhG-CSF in early-stage breast cancer patients receiving chemotherapy in China]. Zhonghua Zhong Liu Za Zhi. 2020. PMID: 33113628. doi:10.3760/cma.j.cn112152-20200616-00565

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。